After Tysabri, Ocrevus Seen as Better Than Gilenya at Preventing Relapse

After Tysabri, Ocrevus Seen as Better Than Gilenya at Preventing Relapse

315809

After Tysabri, Ocrevus Seen as Better Than Gilenya at Preventing Relapse

Ocrevus (ocrelizumab) may be more effective than Gilenya (fingolimod) at preventing relapse in relapsing-remitting multiple sclerosis (RRMS) patients who recently transitioned from Tysabri (natalizumab), according to a new study. Ocrevus is “potentially a better exit strategy than [Gilenya] after [Tysabri] cessation, with an impressive reduction [in] risk of relapse,” the researchers wrote. The study, “Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study,” was published in the Journal of Neurology. Recommended Reading…

You must be logged in to read/download the full post.